gptkbp:instance_of
|
gptkb:pharmaceuticals
|
gptkbp:academic_programs
|
gptkb:Dr._Emily_White
|
gptkbp:acquired
|
gptkb:Uro_Gen_Pharma_Ltd.
|
gptkbp:advertising
|
gptkb:Dr._Sarah_Green
Dr. Nancy Yellow
Dr. Paul Orange
|
gptkbp:awards
|
various industry awards
|
gptkbp:ceo
|
Liz Barrett
|
gptkbp:clinical_trial
|
Phase 3 trials
ongoing studies
|
gptkbp:collaborates_with
|
academic institutions
|
gptkbp:conducts_research_on
|
gptkb:Dr._David_P._M._H._Hwang
|
gptkbp:customer_support
|
gptkb:Dr._George_Wood
|
gptkbp:develops
|
therapeutics for urological cancers
|
gptkbp:employees
|
over 100
|
gptkbp:focuses_on
|
gptkb:disease
bladder cancer
urothelial carcinoma
uro-oncology
|
gptkbp:founded
|
gptkb:2010
|
gptkbp:has_authority_over
|
gptkb:Dr._Tom_Blue
|
gptkbp:head
|
gptkb:Dr._Kevin_Grey
|
gptkbp:head_of_commercial_operations
|
gptkb:Dr._Jane_Smith
|
gptkbp:head_of_state
|
gptkb:Dr._Lisa_Black
gptkb:Dr._Richard_Roe
gptkb:Dr._Alan_Brown
gptkb:Dr._Anna_Gold
gptkb:Dr._Michael_A._M._H._Hwang
Dr. Frank Clay
|
gptkbp:headquarters
|
gptkb:New_York_City
|
https://www.w3.org/2000/01/rdf-schema#label
|
Uro Gen
|
gptkbp:instruction_set
|
multiple drug candidates
|
gptkbp:investment
|
gptkb:Dr._Rachel_Purple
institutional investors
|
gptkbp:military_service
|
gptkb:Dr._Chris_Silver
|
gptkbp:mission
|
improve patient outcomes
|
gptkbp:partnership
|
with Merck
|
gptkbp:product
|
gptkb:Uro_Gen's_RTGel
gptkb:Jelmyto
|
gptkbp:provides_training_for
|
gptkb:Dr._Alice_Steel
|
gptkbp:public_relations
|
gptkb:Dr._Betty_Stone
gptkb:Dr._Steve_Pink
|
gptkbp:regulatory_compliance
|
gptkb:Dr._John_Doe
gptkb:Dr._Julia_Bronze
FDA approved products
|
gptkbp:research_and_development
|
innovative therapies
|
gptkbp:research_areas
|
oncology
urology
|
gptkbp:risk_management
|
gptkb:Dr._Henry_Copper
|
gptkbp:strategic_goals
|
gptkb:Dr._Laura_Cyan
|
gptkbp:supply_chain
|
gptkb:Dr._Mark_Brown
|
gptkbp:traded_on
|
gptkb:NASDAQ
|
gptkbp:website
|
www.urogen.com
|
gptkbp:bfsParent
|
gptkb:Taris_Biomedical
|
gptkbp:bfsLayer
|
5
|